DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,209,246 | -4.3% | 107,089 | +36.8% | 0.01% | 0.0% |
| Q2 2023 | $2,309,246 | +28.1% | 78,253 | 0.0% | 0.01% | +33.3% |
| Q1 2023 | $1,802,949 | -17.2% | 78,253 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $2,176,216 | -9.4% | 78,253 | 0.0% | 0.01% | -20.0% |
| Q3 2022 | $2,402,000 | -11.2% | 78,253 | -14.8% | 0.01% | 0.0% |
| Q2 2022 | $2,705,000 | +9.3% | 91,898 | +19.5% | 0.01% | +25.0% |
| Q1 2022 | $2,475,000 | -6.9% | 76,931 | +29.0% | 0.01% | 0.0% |
| Q4 2021 | $2,659,000 | -3.0% | 59,618 | +9.8% | 0.01% | 0.0% |
| Q3 2021 | $2,740,000 | -31.3% | 54,308 | +6.8% | 0.01% | -38.5% |
| Q2 2021 | $3,989,000 | +41.8% | 50,860 | +3.2% | 0.01% | +30.0% |
| Q1 2021 | $2,813,000 | -40.0% | 49,271 | -12.1% | 0.01% | -41.2% |
| Q4 2020 | $4,692,000 | +81.5% | 56,023 | -22.4% | 0.02% | +70.0% |
| Q3 2020 | $2,585,000 | +27.5% | 72,159 | -14.0% | 0.01% | +25.0% |
| Q2 2020 | $2,028,000 | – | 83,876 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |